COVAXIN's immunogenicity profile has drawn global attention: ICMR

New Delhi: Covaxin, the Indian indigenous vaccine against the novel coronavirus has drawn global attention, said the ICMR on Friday.  “Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves the remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet’s interest in publishing them”, tweeted the top medical body.

It added that encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites.

𝐈𝐧𝐝𝐢𝐚𝐧 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐂𝐎𝐕𝐈𝐃-19 𝐝𝐫𝐚𝐰𝐬 𝐠𝐥𝐨𝐛𝐚𝐥 𝐚𝐭𝐭𝐞𝐧𝐭𝐢𝐨𝐧. The results of the #COVAXIN Phase-2 human clinical trials can be accessed at https://t.co/jjl1WifW2q pic.twitter.com/VKfvjeZuOE

— ICMR (@ICMRDELHI) December 24, 2020

Meanwhile, Bharat Biotech, which is manufacturing the vaccine at its biocontainment facility said that it has successfully recruited 13,000 volunteers for the Phase III clinical trials of Covaxin and the target is to have 26,000 participants.

“This is an unprecedented vaccine trial ever to take place in India, and we are overwhelmed with the steady rise in participation,” Bharat Biotech Joint MD Suchitra Ella said. The company had started the phase III clinical trials in mid-November.

Yesterday, the All India Institute of Medical Sciences (AIIMS), New Delhi had invited volunteers for the Phase III clinical trial of Covaxin.